Enzalutamide

CAS 915087-33-1 29 API suppliersSmall Molecule

Overview

Enzalutamide is an androgen receptor inhibitor used primarily in the treatment of metastatic castration-resistant prostate cancer. It works by blocking the action of male hormones that fuel the growth of cancer cells in the prostate.

API suppliers (29)

Suppliers of Enzalutamide evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India14China7Netherlands2Taiwan1USA1

Country recorded for 25 of 29 suppliers.

16 of 29 hold a GMP certificate on record in the EU or UK registers

Showing 25 of 29 suppliers — see the full list in the app.

Patent & exclusivity (US)

Per the FDA Orange Book (5 approved US products), the latest listed US patent on Enzalutamide expires 23 Feb 2037 and exclusivity 17 Nov 2026. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

Prostate CancerHormonal TherapyCancer
Verified Supplier Partner

Do you supply Enzalutamide? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.